News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
INNOVENT BIO Forms Strategic Collaboration with Pfizer on 12 Projects with Total Deal Value of USD10.5B
INNOVENT BIO (01801.HK) announced that the Group entered into a strategic global licensing and collaboration agreement with Pfizer Inc. (PFE.US) for the research and development of...
Reset
Send
The window will close in 5 seconds
INNOVENT BIO Forms Strategic Collaboration with Pfizer on 12 Projects with Total Deal Value of USD10.5B
Close
Recommend
6
Positive
11
Negative
3
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

INNOVENT BIO (01801.HK)  -2.050 (-2.534%)    Short selling $391.98M; Ratio 32.259%   announced that the Group entered into a strategic global licensing and collaboration agreement with Pfizer Inc. (PFE.US)      for the research and development of 12 promising breakthrough early-stage and de novo cancer medicines.

The partnership includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates (ADCs) with novel differentiated payloads and multi-specific antibodies with differentiated immune-engaging features and unique designs.

Related News M Stanley: Risk-Reward of China Biotech Stocks to Improve in 2H2026
Pursuant to the Agreement, Innovent will receive a US$650 million upfront payment and is eligible for up to US$9.85 billion in development, regulatory and commercial milestone payments, bringing the total value of the deal to up to US$10.5 billion.

The collaboration spans a portfolio of 12 oncology programs, comprising eight Innovent-originated early-stage assets and four Pfizer-proposed discovery programs. According to the Agreement, Innovent will conduct development of these programs through Phase 1 clinical study powered by its proprietary discovery engine and robust early clinical capabilities, after which Pfizer will lead the global development.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-02 16:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.